Ventyx Biosciences Inc. (NASDAQ: VTYX)
$3.06
+0.2200 ( +7.75% ) 641.3K
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Market Data
Open
$3.06
Previous close
$2.84
Volume
641.3K
Market cap
$214.40M
Day range
$2.79 - $3.09
52 week range
$1.87 - $38.20
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 70 | Nov 09, 2023 |
8-k | 8K-related | 13 | Nov 09, 2023 |
8-k | 8K-related | 29 | Nov 06, 2023 |
4 | Insider transactions | 1 | Oct 11, 2023 |
4 | Insider transactions | 1 | Oct 11, 2023 |
8-k | 8K-related | 35 | Oct 10, 2023 |
4 | Insider transactions | 1 | Oct 06, 2023 |
4 | Insider transactions | 1 | Oct 04, 2023 |
4 | Insider transactions | 1 | Oct 04, 2023 |
4 | Insider transactions | 1 | Sep 20, 2023 |